Document is current
Any future updates will be listed below
-
Authors
Piel, Sarah https://orcid.org/0000-0002-1779-3532
McManus, Meagan J.
Heye, Kristina N.
Beaulieu, Forrest
Fazelinia, Hossein
Janowska, Joanna I.
MacTurk, Bryce
Starr, Jonathan
Gaudio, Hunter
Patel, Nisha
Hefti, Marco M.
Smalley, Martin E.
Hook, Jordan N.
Kohli, Neha V.
Bruton, James
Hallowell, Thomas
Delso, Nile
Roberts, Anna
Lin, Yuxi
Ehinger, Johannes K.
Karlsson, Michael
Berg, Robert A.
Morgan, Ryan W.
Kilbaugh, Todd J.
-
Funding
Funding for this research was provided by:
National Institutes of Health National Heart, Lung, and Blood Institute (K23HL148541, R01HL141386)
- License Information
-
More Information
Article History
Received: 1 March 2024
Accepted: 7 June 2024
First Online: 15 June 2024
Competing interests
: S.P., M.K. and J.K.E. have, or have had, salary from and/or equity interest in Abliva AB. S.P., M.K. and J.K.E. have filed patent applications for the use of protected carboxylic acid-based metabolites for treatment of mitochondrial disorders (WO/2017/060400, WO/2017/060418, WO/2017/060422). The remaining authors have no conflicts of interest to disclose.
